Latest News
Cumberland Pharmaceuticals secures FDA Fast Track status for DMD heart‑disease therapy ifetroban
4 February 2026 - American specialty pharmaceutical company Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) said on Wednesday it has received Fast Track Designation from the US Food and Drug Administration for ifetroban, an oral therapy targeting the ...
Hologic receives FDA approval for Aptima HPV assay as primary screening option
4 February 2026 - Women's health company Hologic Inc (Nasdaq:HOLX) announced on Wednesday that the US Food and Drug Administration (FDA) has approved its Aptima HPV Assay for clinician-collected HPV primary screening.The mRNA-based assay is desi...
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
4 February 2026 - Cizzle Biotechnology Holdings plc (LSE: CIZ), a UK-based developer of diagnostic tests for early-stage cancer, announce on Wednesday that it has been granted patent protection in Canada covering methods to measure the CIZ1B lung can...
Viatris names new chief legal officer
4 February 2026 - Global healthcare company Viatris Inc (Nasdaq:VTRS) announced on Tuesday the appointment of Matthew J Maletta as chief legal officer (CLO), effective 9 February 2026.This follows the transition of the company's current CLO, Bri...
Biosion reports first patient dosed in Phase 1a/1b trial of BSI-082
4 February 2026 - Biosion Inc, a China-based clinical-stage biotechnology company developing innovative antibody-based therapeutics, announced on Tuesday that the first patient has been dosed in a Phase 1a/1b Investigator-Initiated Trial (IIT) assess...